The UK’s pharmaceutical and fine chemical industry is accelerating development of a new generation of manufacturing processes thanks to a new drug manufacturing innovation facility.
The state-of-the-art Medicines Manufacturing Innovation Centre (MMIC) will be located in Renfrewshire, Scotland, and led by the Centre for Process Innovation (CPI) in partnership with the University of Strathclyde, the Medicines Manufacturing Industry Partnership (MMIP), and founding industry partners, AstraZeneca and GSK. The centre will ensure the UK is a technology and innovation leader in small molecule pharmaceutical and fine chemical manufacturing, thereby boosting the competitiveness of both sectors.
The new manufacturing centre is funded by several sources including UK Research and Innovation, Scottish Enterprise and founding industry partners GlaxoSmithKline and AstraZeneca.
The facility and infrastructure project will be established over a three-year period, starting in summer 2018, and could to create up to 80 high value jobs by 2023. A further 90 jobs will be created or retained during design and construction. Indirect employment will be generated through start-ups, SMEs and large companies that will grow their businesses using the transformative manufacturing technologies developed within the MMIC.
The centre aims to become an international beacon for innovation in small molecule medicines manufacturing, and will incorporate capabilities for development and manufacturing of drug substances and drug products in a GMP-capable environment.